Unfortunately, Gemzar® has only demonstrated a modest median OS rate of 5.7 months and one-year probability of survival of 18%. To date, the only successful combination approved by the FDA is Gemzar® and Roche’s (OTCQX: RHHBY) Tarceva®, which hasn’t set the world on fire either. This combination barely increased the median overall survival rate to 6.4 months (from 6.0) and increased the one-year survival rate to 23.8%. These results compare with the results of the trial carried out with the encapsulated cells which showed a doubling of the median survival rate from 24 weeks for Gemzar® to 40 weeks for the encapsulated cell regime and a shift from the 18% to 36% one-year survival rate, all of which occurred with only 2 treatment cycles.
Market Data 
Markets 
AI
